Samir Ounzain
@ispiyou
Followers
1K
Following
4K
Media
100
Statuses
6K
Scientist/CEO @HAYA_lncRNA (https://t.co/x9N85dFuqJ) Interested in the dark side of your genome and the RNAs produced by it #lncRNA
Lausanne, Switzerland
Joined February 2011
Brilliant podcast with Samir Ounzain as he shares his journey & what led to the founding of HAYA Therapeutics; a biotech trailblazing an entirely new approach to treating common & chronic diseases by cell reprogramming via the regulatory genome. 🧬❤️🫁 https://t.co/Bn1mgdnDNU
0
2
7
Super excited that we get to take this next step in the future of Haya Therapeutics! 🧬 🚀
🚀 We're thrilled to announce that #HAYATherapeutics have successfully raised $65Million in #SeriesA round of financing 🎉 A huge #THANKYOU to our TEAM, PARTNERS, and INVESTORS! 🙌 ➡️ https://t.co/lsRTHv8PbR
@SofinnovaVC @EarlybirdVC
9
1
37
🚀 We're thrilled to announce that #HAYATherapeutics have successfully raised $65Million in #SeriesA round of financing 🎉 A huge #THANKYOU to our TEAM, PARTNERS, and INVESTORS! 🙌 ➡️ https://t.co/lsRTHv8PbR
@SofinnovaVC @EarlybirdVC
0
7
17
I’m really thrilled to join up with Samir and the team at HAYA Therapeutics as their new Chief Business Officer!
📣 Today, we are thrilled to welcome @drrichjlaw as #HAYATherapeutics’ #CBO! Looking forward to the future ahead of us. Stay tuned for more exciting news! https://t.co/vSUJIWIbCt Welcome to the team Richard!🎉
10
1
39
Thrilled to welcome Rich as our new Chief Business Officer! Rich has a stellar track record in biopharma partnerships, strategic growth, and innovation and his expertise at the intersection of biology and technology has helped reshape drug discovery!
I’m really thrilled to join up with Samir and the team at HAYA Therapeutics as their new Chief Business Officer!
0
1
3
📣 Today, we are thrilled to welcome @drrichjlaw as #HAYATherapeutics’ #CBO! Looking forward to the future ahead of us. Stay tuned for more exciting news! https://t.co/vSUJIWIbCt Welcome to the team Richard!🎉
1
3
13
This week, our podcast guest is Samir Ounzain, CEO of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’
0
2
2
👇🤯For everybody interested in #lncRNAs, the latest @GencodeGenes capture effort and resulting improved annotations are big news! Major increases in overall counts in human and mouse, better overlap with other collections and far higher human-mouse orthology rates
The latest preprint from GENCODE focuses on expanding and unifying lncRNA annotations. GENCODE: massively expanding the lncRNA catalog through capture long-read RNA sequencing https://t.co/t0zAYpy3aN
@_Rory_Johnson_ @GOLDLab_UCD @GuigoLab @RodericGuigo @GencodeGenes
0
8
27
Breaking news! HAYA Therapeutics wins Major Collaboration with Lilly 🚀🧬🇨🇭🌐 HAYA Therapeutics, a Swiss biotechnology startup pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and
0
3
7
Under a multi-year agreement announced Wednesday, @EliLillyandCo will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions. #pharma #biospace
https://t.co/FH9jDWFsLY
biospace.com
Under a multi-year agreement announced Wednesday, Eli Lilly will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions.
0
2
2
𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐍𝐞𝐰𝐬: The Co-Founder and CEO of @HAYA_lncRNA describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease. Full video: https://t.co/sH7VZMPps5
1
3
11
4September: How does @EliLillyandCo plan to apply @HAYA_lncRNA's long noncoding RNA platform to make new drugs to treat #obesity and metabolic disorders? Read what HAYA CEO Samir Ounzain, PhD told me in my latest for @GENbio:
genengnews.com
HAYA is developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in tissues that include lungs, kidneys, liver, and the micro-environment of solid...
0
2
6
🚀 We are thrilled to announce a multi-year #collaboration with @EliLillyandCo to discover novel #RegulatoryGenome targets for #Obesity & related #MetabolicConditions. Learn more: https://t.co/oYYXlKS1IX
0
9
16
This month began with #WorldRNADay, but at #HAYA, every day is RNA day! 🌍🧬 RNA isn't just a messenger from our DNA—it's a key player in evolution, cell biology, and a game-changer in therapeutics. 🚀 Learn more: https://t.co/qJF47677y4
1
4
8
Excited to soon embark on a year-long sabbatical in Lausanne 🇨🇭as a visiting prof in @Trono_Lab @EPFL_en! It’s only an “au revoir”, lab 💕👋
5
2
93
Proud of our #startupfit alumni! ✨✨✨ Inaugural European entrepreneur award crowns HAYA Therapeutics Founders https://t.co/C03WDMs8wy via @startuptickerch #Swisstech #VDtech @HAYA_lncRNA
0
2
6
Andreas & Thomas Struengmann Award Honors HAYA Therapeutics Co-founders as Inaugural Winners https://t.co/8a2brEWyAU
0
1
1
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award https://t.co/Um0xzJVa6A
0
1
1
HAYA co-founders, CEO Samir Ounzain (@ispiyou) and CTO Daniel Blessing, were honored with the inaugural Andreas & Thomas Struengmann Award on Friday night. The award recognizes DACH-region life science entrepreneurs developing revolutionary technologies. https://t.co/BNH1NJ3Okt
0
2
4
I spoke with @elaineywchen about the results of #HELIOS-B https://t.co/s1PAfWU7Rj Certainly I was not expecting these results. A pleasant surprise. Need to dive into the data to understand the meaning of what was reported. Some of the reported data include parts of the OLE
statnews.com
Alnylam Pharmaceuticals said its treatment for an increasingly common heart condition cut the risk of death and recurrent cardiovascular complications in a key study.
A big deal, medically and financially. Alnylam reports positive results for cardiovascular drug in pivotal study. By @elaineywchen $alny
0
3
11